JP2008544979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008544979A5 JP2008544979A5 JP2008518998A JP2008518998A JP2008544979A5 JP 2008544979 A5 JP2008544979 A5 JP 2008544979A5 JP 2008518998 A JP2008518998 A JP 2008518998A JP 2008518998 A JP2008518998 A JP 2008518998A JP 2008544979 A5 JP2008544979 A5 JP 2008544979A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- oxazepan
- oxazolidine
- phenyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- -1 oxazepan-4-yl-phenyl Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 208000035143 Bacterial infection Diseases 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 3
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 241000588621 Moraxella Species 0.000 claims 2
- 241000186367 Mycobacterium avium Species 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- FOCOZKMFTFOPCZ-UHFFFAOYSA-N 1,3-oxazolidine-5-carboxamide Chemical compound NC(=O)C1CNCO1 FOCOZKMFTFOPCZ-UHFFFAOYSA-N 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241001112695 Clostridiales Species 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010014666 Endocarditis bacterial Diseases 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000001860 Eye Infections Diseases 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- OIBLANUWJYFXGT-UHFFFAOYSA-N N-methyl-1,3-oxazolidine-5-carboxamide Chemical compound CNC(=O)C1CNCO1 OIBLANUWJYFXGT-UHFFFAOYSA-N 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000009361 bacterial endocarditis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 208000011323 eye infectious disease Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000007119 infective endocarditis Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 150000003852 triazoles Chemical group 0.000 claims 1
- 0 Cc1c(*)c(N(CC(*)O2)C2=O)cc(*)c1N1C(CC2)[C@@]2CO[C@@]2C1C2 Chemical compound Cc1c(*)c(N(CC(*)O2)C2=O)cc(*)c1N1C(CC2)[C@@]2CO[C@@]2C1C2 0.000 description 1
Claims (16)
- 式Iの化合物
Xは、−C(=O)NHR4、またはCH2−hetであり、
R1、R2、R3は、それぞれ独立にHまたはFであり、
R4は、H、C1〜6アルキル、またはOC1〜6アルキルであり、
hetは、非過酸化物酸素、硫黄、および窒素からなる群から選択される1、2または3個のヘテロ原子を環内に有する五(5)員複素環であり、hetは、1〜3個のハロ、C1〜4アルキル、エチレン、エチニル、CN、N3、O(C=O)C1〜4アルキル、NH2、NHC(=O)C1〜4アルキル、またはC(=O)C1〜4アルキルで置換されていてもよく、
各点線「...」は、それぞれ独立に一重結合または不在であり、かつ
存在ごとに、C1〜6アルキルは、1〜3個のハロ、OH、OC1〜4アルキル、CN、N3、O(C=O)C1〜4アルキル、NH2、NHC(=O)C1〜4アルキル、またはC(=O)C1〜4アルキルによって置換されていてもよい]
またはその薬学的に許容できる塩。 - R4がH、−CH3、または−CH2CH3である、請求項2に記載の化合物、またはその薬学的に許容できる塩。
- R4が−OCH3、または−OCH2CH3である、請求項2に記載の化合物、またはその薬学的に許容できる塩。
- hetがトリアゾールである、請求項1に記載の化合物、またはその薬学的に許容できる塩。
- (1)3−(4−[1,4]オキサゼパン−4−イル−フェニル)−2−オキソ−オキサゾリジン−5−カルボン酸アミド、
(2)3−(4−[1,4]オキサゼパン−4−イル−フェニル)−2−オキソ−オキサゾリジン−5−カルボン酸メチルアミド、
(3)3−(3−フルオロ−4[1,4]オキサゼパン−4−イル−フェニル)−2−オキソ−オキサゾリジン−5−カルボン酸アミド、
(4)3−(3−フルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)−2−オキソ−オキサゾリジン−5−カルボン酸メチルアミド、
(5)3−(3,5−ジフルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)−2−オキソ−オキサゾリジン−5−カルボン酸アミド、
(6)3−(3,5−ジフルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)−2−オキソ−オキサゾリジン−5−カルボン酸メチルアミド、
(7)2−オキソ−3−(2,3,5−トリフルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)オキサゾリジン−5−カルボン酸アミド、
(8)2−オキソ−3−(2,3,5−トリフルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)オキサゾリジン−5−カルボン酸メチルアミド、
(9)3−(3,5−ジフルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)−5−[1,2,3]トリアゾール−1−イルメチル−オキサゾリジン−2−オン、または
(10)3−(3,5−ジフルオロ−4−[1,4]オキサゼパン−4−イル−フェニル)−5−(4−エチニル−[1,2,3]トリアゾール−1−イルメチル)−オキサゾリジン−2−オン
である、請求項1に記載の化合物、またはその薬学的に許容できる塩。 - 請求項1に記載の化合物またはその薬学的に許容できる塩、および薬学的に許容できる担体を含む医薬組成物。
- 哺乳動物において、細菌感染症を治療するための、請求項1に記載の化合物またはその薬学的に許容できる塩を含む医薬組成物。
- 経口、非経口、局所、直腸、または鼻腔内投与によって治療するための、請求項8に記載の医薬組成物。
- 前記化合物が、約0.1〜約100mg/kg体重/日の量で投与される、請求項8に記載の医薬組成物。
- 前記化合物が、約1〜約50mg/kg体重/日の量で投与される、請求項8に記載の医薬組成物。
- 前記細菌感染症が、耳の感染症、眼の感染症、呼吸器感染症、皮膚および皮膚組織感染症、細菌性心内膜炎、骨髄炎、心内膜炎または糖尿病性足病変である、請求項8に記載の医薬組成物。
- グラム陽性菌、グラム陰性菌、嫌気性生物、または抗酸菌が原因である細菌感染症を治療するための、請求項8に記載の医薬組成物。
- ブドウ球菌、連鎖球菌、腸球菌、ヘモフィルス、モラクセラ、バクテロイデス、クロストリジウム、マイコバクテリア、またはクラミジアを含む細菌が原因である細菌感染症を治療するための、請求項8に記載の医薬組成物。
- ブドウ球菌が黄色ブドウ球菌(S.aureus)または表皮ブドウ球菌(S.epidermidis)であり、連鎖球菌が化膿連鎖球菌(S.pyogenes)または肺炎連鎖球菌(S.pneumoniae)であり、腸球菌がE.フェカーリス(E.faecalis)であり、ヘモフィルスがインフルエンザ菌(H.influenzae)であり、モラクセラがM.カタラーリス(M.catarrhalis)であり、マイコバクテリアが結核菌(M.tuberculosis)または鳥型結核菌(Mycobacterium avium)である、請求項14に記載の医薬組成物。
- 多剤耐性黄色ブドウ球菌が原因である細菌感染症を治療するための、請求項8に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69486205P | 2005-06-29 | 2005-06-29 | |
PCT/IB2006/001730 WO2007000644A1 (en) | 2005-06-29 | 2006-06-20 | Homomorpholine oxazolidinones as antibacterial agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008544979A JP2008544979A (ja) | 2008-12-11 |
JP2008544979A5 true JP2008544979A5 (ja) | 2009-07-30 |
Family
ID=37101665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518998A Withdrawn JP2008544979A (ja) | 2005-06-29 | 2006-06-20 | 抗菌剤としてのホモモルホリンオキサゾリジノン |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1899331B1 (ja) |
JP (1) | JP2008544979A (ja) |
AT (1) | ATE449773T1 (ja) |
CA (1) | CA2610978A1 (ja) |
DE (1) | DE602006010702D1 (ja) |
DK (1) | DK1899331T3 (ja) |
ES (1) | ES2335307T3 (ja) |
WO (1) | WO2007000644A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101460495B (zh) | 2006-03-31 | 2013-08-14 | 财团法人乙卯研究所 | 具有杂环的化合物 |
JP5455906B2 (ja) * | 2007-08-06 | 2014-03-26 | ミクウルク ファーマシューティカルズ,インコーポレイテッド | 細菌感染症治療のための抗微生物性オルト−フルオロフェニルオキサゾリジノン |
EP2233484A3 (en) * | 2007-10-02 | 2012-04-04 | Research Foundation Itsuu Laboratory | Oxazolidinone derivatives having a 7-membered heterocyclic ring |
WO2015127316A1 (en) | 2014-02-21 | 2015-08-27 | Micurx Pharmaceuticals, Inc. | Water-soluble o-carbonyl phosphoramidate prodrugs for therapeutic administration |
CA2990260A1 (en) * | 2015-07-17 | 2017-01-26 | The Global Alliance For Tb Drug Development, Inc. | Substituted phenyloxazolidinones for antimicrobial therapy |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
US5952324A (en) | 1994-11-15 | 1999-09-14 | Pharmacia & Upjohn Company | Bicyclic oxazine and thiazine oxazolidinone antibacterials |
CA2303959A1 (en) | 1997-11-12 | 1999-05-20 | Pharmacia & Upjohn Company | Oxazolidinone derivatives and pharmaceutical compositions |
JP2000204084A (ja) | 1998-11-11 | 2000-07-25 | Hokuriku Seiyaku Co Ltd | チオカルバミド酸誘導体 |
AU764980B2 (en) | 1998-11-27 | 2003-09-04 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
US6297242B1 (en) | 1999-08-12 | 2001-10-02 | Ortho-Mcneil Pharmaceutical, Inc. | N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof |
SK7572002A3 (en) | 1999-12-21 | 2002-12-03 | Upjohn Co | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
AU5311301A (en) | 2000-04-20 | 2001-11-07 | Upjohn Co | Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis |
ATE301474T1 (de) | 2000-06-30 | 2005-08-15 | Pharmacia & Upjohn Co Llc | Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten |
GB0017225D0 (en) | 2000-07-14 | 2000-08-30 | Really Useful Products Limited | Container |
DE10034627A1 (de) | 2000-07-17 | 2002-01-31 | Bayer Ag | Aryl-substituierte Oxazolidinone mit Cytokin inhibitorischer Wirkung |
US6734307B2 (en) | 2000-07-17 | 2004-05-11 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
WO2003008389A1 (en) | 2001-07-16 | 2003-01-30 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as potential antimicrobials |
ATE507486T1 (de) | 2000-08-24 | 2011-05-15 | Sirf Tech Inc | Vorrichtung zur reduzierung von autokorrelation und kreuzkorrelation bei schwachen cdma-signalen |
PE20020578A1 (es) | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
MXPA03006958A (es) | 2001-02-05 | 2003-11-18 | Upjohn Co | Composicion para administracion rectal de farmaco antibacterial de oxazolidinona. |
DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
ES2268011T3 (es) | 2001-04-07 | 2007-03-16 | Astrazeneca Ab | Oxazolidinonas que contienen un grupo sulfonimida como antibioticos. |
GB0108793D0 (en) | 2001-04-07 | 2001-05-30 | Astrazeneca Ab | Chemical compounds |
US6956040B2 (en) | 2001-07-16 | 2005-10-18 | Ranbaxy Laboratories Limited | Oxazolidinone piperazinyl derivatives as potential antimicrobials |
TW200302095A (en) | 2002-01-25 | 2003-08-01 | Upjohn Co | Oxazolidinone cotherapy |
EP1478404A1 (en) | 2002-02-22 | 2004-11-24 | Pharmacia Corporation | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
AU2003213210A1 (en) | 2002-02-22 | 2003-09-09 | Pharmacia Corporation | Ophthalmic formulation with gum system |
AR038536A1 (es) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
IL163688A0 (en) | 2002-02-28 | 2005-12-18 | Astrazeneca Ab | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and theiruse as antibacterial agents |
PL372090A1 (en) | 2002-02-28 | 2005-07-11 | Astrazeneca Ab | Chemical compounds |
WO2003084534A1 (en) | 2002-03-29 | 2003-10-16 | Pharmacia & Upjohn Company Llc | Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections |
WO2003093247A2 (en) | 2002-04-30 | 2003-11-13 | Orchid Chemicals & Pharmaceuticals Ltd | Antibacterial agents |
TW200403240A (en) | 2002-06-28 | 2004-03-01 | Upjohn Co | Difluorothioacetamides of oxazolidinones as antibacterial agents |
WO2004009587A1 (en) | 2002-07-22 | 2004-01-29 | Orchid Chemicals & Pharmaceuticals Ltd | Oxazolidinone derivatives as antibacterial agents |
BR0215921A (pt) | 2002-07-29 | 2005-09-13 | Ranbaxy Lab Ltd | Derivados de oxazolidinona utilizáveis como antimicrobianos e processo de sua preparação |
EP1578734A1 (en) | 2002-08-22 | 2005-09-28 | Orchid Chemicals and Pharmaceuticals Ltd | Novel antibacterial agents |
-
2006
- 2006-06-20 AT AT06779767T patent/ATE449773T1/de not_active IP Right Cessation
- 2006-06-20 DE DE602006010702T patent/DE602006010702D1/de active Active
- 2006-06-20 CA CA002610978A patent/CA2610978A1/en not_active Abandoned
- 2006-06-20 DK DK06779767.0T patent/DK1899331T3/da active
- 2006-06-20 JP JP2008518998A patent/JP2008544979A/ja not_active Withdrawn
- 2006-06-20 EP EP06779767A patent/EP1899331B1/en not_active Not-in-force
- 2006-06-20 ES ES06779767T patent/ES2335307T3/es active Active
- 2006-06-20 WO PCT/IB2006/001730 patent/WO2007000644A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009526832A5 (ja) | ||
US20100286211A1 (en) | Oxazolidinone derivatives as antimicrobials | |
AU2014208965B2 (en) | Compounds and methods for treating bacterial infections | |
AU782078B2 (en) | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents | |
US20010047004A1 (en) | Oxazolidinone thioamides with piperazine amide substituents | |
JP2008544979A5 (ja) | ||
CA2513463A1 (en) | Gyrase inhibitors and uses thereof | |
WO1997030981A1 (en) | Azolyl piperazinyl phenyl oxazolidinone antimicrobials | |
CA2489128A1 (en) | 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections | |
EP1030852B1 (en) | Oxazolidinone derivatives and pharmaceutical compositions | |
JP4607107B2 (ja) | シクロプロピル基置換されたオキサゾリジノン抗生物質およびこれらの誘導体 | |
JP2004525876A (ja) | 抗細菌活性を有する新規複素環式化合物、それらの調製方法、およびそれらを含有する薬学的組成物 | |
EP3500567A1 (en) | Antibiotic compounds | |
US6686363B2 (en) | Cyclopropyl containing oxazolidinone antibiotics and derivatives thereof | |
US6642238B2 (en) | Oxazolidinone thioamides with piperazine amide substituents | |
JP2008543964A5 (ja) | ||
JP2008544979A (ja) | 抗菌剤としてのホモモルホリンオキサゾリジノン | |
JP2008534672A5 (ja) | ||
JP2008546825A5 (ja) | ||
Hauck et al. | New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics | |
JP2009525318A5 (ja) | ||
JP2009526036A5 (ja) | ||
AU2002362028B2 (en) | Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof | |
JP2006342109A5 (ja) | ||
WO2006018682A2 (en) | Oxazolidinone derivatives as antimicrobials |